Evidence map›Paper›PMID 29968489›Full record

ArticleAIDS research and human retroviruses2018

Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy.

Asha R Kallianpur, Mariana Gerschenson, Todd Hulgan, Harpreet Kaur, David B Clifford, David W Haas, Deborah G Murdock, Justin C McArthur, David C Samuels, David M Simpson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Asha R Kallianpur1 Department of Genomic Medicine, Cleveland Clinic Foundation/Lerner Research Institute , Cleveland, Ohio.
Mariana Gerschenson3 Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii , Honolulu, Hawaii.
Todd Hulgan4 Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee.
Harpreet Kaur1 Department of Genomic Medicine, Cleveland Clinic Foundation/Lerner Research Institute , Cleveland, Ohio.
David B Clifford5 Department of Neurology, Washington University in Saint Louis , St. Louis, Missouri.
David W Haas4 Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee.
Deborah G Murdock6 Children's Hospital of Philadelphia Research Institute & Center for Mitochondrial and Epigenomic Medicine , Philadelphia, Pennsylvania.
Justin C McArthur7 Department of Neurology, Johns Hopkins University School of Medicine , Baltimore, Maryland.
David C Samuels8 Department of Molecular Physiology and Biophysics, Vanderbilt University , Nashville, Tennessee.
David M Simpson9 Icahn School of Medicine of Mount Sinai , New York, New York.
Vanderbilt University Medical Center · USCleveland Clinic Lerner College of Medicine · USJohns Hopkins Medicine · USUniversity of Hawaiʻi at Mānoa · USVanderbilt University · USWashington University in St. Louis · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
The Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Benjamin C. Fogelgren · 2017 to 2026
$59.5M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI ALBERT, RICHARD K · 1985 to 2008
$52.6M
ZIPRASIDONE (GEODON) AUGMENTATION IN SEROTONIN REUPTAKE INHIBITOR-RESISTANT OBM01RR000071 · NCRR · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GOODMAN, MARC T · 1985 to 2009
$41.5M
USING EEG COMPLEXITY AND HIGH PERFORMANCE COMPUTING TO PROFILE SLEEPP20RR016467 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI HOLMES, ERIC · 2001 to 2011
$24.5M
TRPA1 Physiology in Diabetes, Metabolic Syndrome, and MetabolismP20GM113134 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI Michael A. Ortega · 2017 to 2026
$21.5M
WOMEN'S HEALTH AGENDAU01AI025859 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI GOLDMAN, MITCHELL · 1987 to 2008
$14.5M
YOHIMBINE CHALLENGE IN PARKINSONIAN PATIENTS WITH PANIC DISORDERM01RR000044 · NCRR · UNIVERSITY OF ROCHESTER · PI GUZICK, DAVID S · 1985 to 2006
$13.8M
NCRR NIH HHS M01 RR000044NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000071NCRR NIH HHS P20 RR016467NHLBI NIH HHS R21 HL087726NIAID NIH HHS R01 AI077505NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI025903NIAID NIH HHS U01 AI027658NIAID NIH HHS U01 AI027664NIAID NIH HHS U01 AI027668NIAID NIH HHS U01 AI027670NIAID NIH HHS U01 AI032770NIAID NIH HHS U01 AI034853NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI046370NIAID NIH HHS U01 AI046376NIAID NIH HHS U01 AI046386NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIGMS NIH HHS P20 GM113134NIMHD NIH HHS U54 MD007601NINDS NIH HHS K24 NS002253NINDS NIH HHS R01 NS032228NINDS NIH HHS R01 NS044807NINDS NIH HHS R21 NS059330NINDS NIH HHS U01 NS032228
6 · The paper itself

Abstract

Some HIV-associated complications involve mitochondrial dysfunction and may be less common in individuals with iron-loading HFE (hemochromatosis gene) variants. We evaluated HFE 845A and 187G alleles in relation to mitochondrial DNA (mtDNA) levels in peripheral blood mononuclear cells from 85 individuals with HIV infection on uninterrupted antiretroviral therapy (ART) for 15 or more consecutive weeks. Carriers of HFE gene variants (N = 24) had significantly higher mtDNA levels than noncarriers (N = 61), after adjusting for age, race, sex, and type of ART [adjusted β-coefficient 297, p-value < .001 for at least one HFE variant], but mtDNA declined among all individuals on study during 48 weeks on ART. Increased cellular mtDNA content may represent a compensatory response to mitochondrial stress that is influenced by iron-loading HFE variants.

Indexed as

AdultAllelesAnti-HIV AgentsCase-Control StudiesCD4 Lymphocyte CountDNA Copy Number VariationsDNA, MitochondrialFemaleGenotypeHemochromatosis ProteinHIV-1HIV InfectionsHumansLeukocytes, MononuclearMaleMiddle AgedAnti-HIV AgentsDNA, MitochondrialHemochromatosis ProteinHFE protein, humanRNA, ViralalleleARTHFEmtDNA

Identifiers

PMID29968489
PMCPMC6421985
OpenAlexW2811282730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.